Browsing by Author "Bautista-Molano, Wilson"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Assessment of SpondyloArthritis International Society (ASAS) consensus on Spanish nomenclature for spondyloarthritis(2020) Navarro-Compán, Victoria; Otón, Teresa; Loza, Estíbaliz; Almodóvar, Raquel; Ariza-Ariza, Rafael; Bautista-Molano, Wilson; Burgos-Vargas, Rubén; Collantes-Estévez, Eduardo; Miguel, Eugenio de; González-Fernández, Carlos; Gratacós, Jordi; Ibáñez, Sebastián; Juanola, Xavier; Maldonado-Cocco, José; Moltó, Anna; Mulero, Juan; Pacheco-Tena, Cesar; Ramos-Remus, Cesar; Sanz-Sanz, Jesús; Valle-Onate, Rafael; Zarco, Pedro; Marzo-Ortega, HelenaObjective: To develop a consensus to standardise the use of Spanish terms, abbreviations and acronyms in the field of spondyloarthritis (SpA). Methods: An international task force comprising all native Spanish-speaking Assessment of SpondyloArthritis International Society (ASAS) members, the executive committee of Grupo para el estudio de la Espondiloartritis de la Sociedad Espanola ˜ de Reumatología (GRESSER), two methodologists, two linguists from the Real Academia Nacional de Medicina de Espana˜ (RANM) and two patients from the Spanish Coordinator of Spondylitis Associations (CEADE) was established. A literature review was performed to identify the conflicting terms/abbreviations/acronyms in SpA. This review examined written sources in Spanish including manuscripts, ICF and ICD, guidelines, recommendations and consensuses. This was followed by a nominal group meeting and a three-round Delphi. The recommendations from the RANM based on the Panhispanic dictionary were followed throughout the process. Results: Consensus was reached for 46 terms, abbreviations or acronyms related to the field of SpA. A Spanish translation was accepted for 6 terms and 6 abbreviations to name or classify the disease, and for 6 terms and 4 abbreviations related to SpA. It was agreed not to translate 15 acronyms into Spanish. However, when mentioning them, it was recommended to follow this structure: type of acronym in Spanish and acronym and expanded form in English. With regard to 7 terms or abbreviations attached to acronyms, it was agreed to translate only the expanded form and a translation was also selected for each of themPublication Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis(2023) Bautista-Molano, Wilson; Fernández-Avila, Daniel G.; Brance, María Lorena; Avila Pedretti, María Gabriela; Burgos-Vargas, Ruben; Corbacho, Inés; Cosentino, Vanesa Laura; Díaz Coto, José Francisco; Giraldo Ho, Enrique; Gomes Resende, Gustavo; Gutiérrez, Luis Arturo; Gutiérrez, Marwin; Ibáñez, Sebastián; Jáuregui, Edwin; Ocampo, Vanessa; Palleiro Rivero, Daniel Ruben; Palominos, Penélope Esther; Pacheco Tena, Cesar; Quiceno, Guillermo Andrés; Saldarriaga-Rivera, Lina María; Sommerfleck, Fernando Andrés; Sariego Goecke, Anelisse; Vera Barrezueta, Claudia; Vega Espinoza, Luis Enrique; Vega Hinojosa, Oscar; Citera, Gustavo; Lozada, Carlos; Sampaio-Barros, Percival D.; Schneeberger, Emilce; Soriano, Enrique R.Axial spondyloarthritis (axSpA) comprises a spectrum of chronic inflammatory manifestations affecting the axial skeleton and represents a challenge for diagnosis and treatment. Our objective was to generate a set of evidence-based recommendations for the management of axSpA for physicians, health professionals, rheumatologists and policy decision makers in Pan American League of Associations for Rheumatology (PANLAR) countries. Grading of Recommendations, Assessment, Development and Evaluation-ADOLOPMENT methodology was used to adapt existing recommendations after performing an independent systematic search and synthesis of the literature to update the evidence. A working group consisting of rheumatologists, epidemiologists and patient representatives from countries within the Americas prioritized 13 topics relevant to the context of these countries for the management of axSpA. This Evidence-Based Guideline article reports 13 recommendations addressing therapeutic targets, the use of NSAIDs and glucocorticoids, treatment with DMARDs (including conventional synthetic, biologic and targeted synthetic DMARDs), therapeutic failure, optimization of the use of biologic DMARDs, the use of drugs for extra-musculoskeletal manifestations of axSpA, non-pharmacological interventions and the follow-up of patients with axSpA.